Barnes T A, McDonald J, Rowbotham D J, Duarte T L, Lambert D G
Department of Cardiovascular Sciences (Pharmacology and Therapeutics Group), Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, UK.
Naunyn Schmiedebergs Arch Pharmacol. 2007 Nov;376(3):217-25. doi: 10.1007/s00210-007-0189-z. Epub 2007 Sep 25.
Pretreatment of the G-protein coupled nociceptin receptor (NOP) with nociceptin/orphaninFQ (N/OFQ) produces desensitisation. The influences of receptor expression and genomic effects are largely unknown. We have used an ecdysone-inducible NOP expression system in a CHO line (CHO INDhNOP) to examine the effects of N/OFQ pretreatment upon receptor density, GTPgamma[35S] binding, cAMP formation and NOP-mRNA. CHO(INDhNOP) induced with 5 and 10 microM PonasteroneA (PonA) for 20 h produced NOP densities (Bmax) of 194 and 473 fmol. mg(-1) protein, respectively. This was accompanied by decreased NOP mRNA. The lower Bmax is typical of the central nervous system. Pretreatment with 1 microM N/OFQ significantly (p < 0.05) reduced Bmax at 5 and 10 microM PonA to 100 and 196 fmol. mg(-1) protein, respectively. There was no change in binding affinity. Along with the reduction in Bmax), potency and efficacy for N/OFQ-stimulated GTPgamma[35S] binding were also reduced (5 microM PonA: pEC50-control = 8.55 +/- 0.06, pretreated = 7.88 +/- 0.07; Emax-control = 3.52 +/- 0.43, pretreated = 2.48 +/- 0.10; 10 microM PonA: pEC50-control = 8.41 +/- 0.18, pretreated = 7.76 +/- 0.03; Emax-control = 5.07 +/- 0.17, pretreated = 3.38 +/- 0.19). For inhibition of cAMP formation, there was a reduction in potency (5 microM PonA: pEC50-control = 9.78 +/- 0.08, pretreated = 8.92 +/- 0.13; 10 microM PonA: pEC50-control = 9.99 +/- 0.07, pretreated = 9.04 +/- 0.14), but there was no reduction in efficacy. In addition, there were 39 and 31% reductions in NOP mRNA at 5 and 10 microM PonA, respectively, but these measurements were made following concurrent N/OFQ challenge and PonA induction. In CHO INDhNOP, we have shown a reduction in cell surface receptor numbers and a reduction in functional coupling after N/OFQ pretreatment. This was observed at pseudo-physiological and supraphysiological receptor densities. Moreover, we also report a reduction in NOP mRNA, but further studies are needed which include 'pulsing' PonA and desensitizing following wash-out.
用痛敏肽/孤啡肽FQ(N/OFQ)对G蛋白偶联痛敏肽受体(NOP)进行预处理会产生脱敏作用。受体表达和基因组效应的影响在很大程度上尚不清楚。我们在一个CHO细胞系(CHO INDhNOP)中使用了蜕皮激素诱导的NOP表达系统,以研究N/OFQ预处理对受体密度、GTPγ[35S]结合、cAMP形成和NOP-mRNA的影响。用5和10 microM的ponasteroneA(PonA)诱导CHO(INDhNOP) 20小时,产生的NOP密度(Bmax)分别为194和473 fmol·mg(-1) 蛋白。这伴随着NOP mRNA的减少。较低的Bmax是中枢神经系统的典型特征。用1 microM N/OFQ预处理显著(p < 0.05)将5和10 microM PonA时的Bmax分别降至100和196 fmol·mg(-1) 蛋白。结合亲和力没有变化。随着Bmax的降低,N/OFQ刺激的GTPγ[35S]结合的效力和效能也降低了(5 microM PonA:pEC50对照 = 8.55 +/- 0.06,预处理 = 7.88 +/- 0.07;Emax对照 = 3.52 +/- 0.43,预处理 = 2.48 +/- 0.10;10 microM PonA:pEC50对照 = 8.41 +/- 0.18,预处理 = 7.76 +/- 0.03;Emax对照 = 5.07 +/- 0.17,预处理 = 3.38 +/- 0.19)。对于cAMP形成的抑制,效力降低了(5 microM PonA:pEC50对照 = 9.78 +/- 0.08,预处理 = 8.92 +/- 0.13;10 microM PonA:pEC50对照 = 9.99 +/- 0.07,预处理 = 9.04 +/- 0.14),但效能没有降低。此外,在5和10 microM PonA时,NOP mRNA分别降低了39%和31%,但这些测量是在同时进行N/OFQ刺激和PonA诱导后进行的。在CHO INDhNOP中,我们已经证明N/OFQ预处理后细胞表面受体数量减少,功能偶联减少。这在假生理和超生理受体密度下都观察到了。此外,我们还报告了NOP mRNA的减少,但需要进一步的研究,包括“脉冲式”给予PonA以及洗脱后的脱敏研究。